-
EP2079732
European procedure
Extract from the Register of European Patents
EP About this file: EP2079732
| EP2079732 - 3- (1, 3-BENZ0DI0X0L-5-YL) -6- (4-CYCLOPROPYLPIPERAZIN-1-YL) -PYRIDAZINE, ITS SALTS AND SOLVATES AND ITS USE AS HISTAMINE H3 RECEPTOR ANTAGONIST [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 26.10.2012 Database last updated on 23.11.2024 | Most recent event Tooltip | 26.10.2012 | No opposition filed within time limit | published on 28.11.2012 [2012/48] | Applicant(s) | For all designated states High Point Pharmaceuticals, LLC 4170 Mendenhall Oaks Parkway High Point, NC 27265 / US | [2009/30] | Inventor(s) | 01 /
HOHLWEG, Rolf Nederste Torpenvej 29 DK-3050 Humlebæk / DK | [2009/30] | Representative(s) | Gillard, Richard Edward, et al Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus London EC1N 2HA / GB | [N/P] |
| Former [2012/02] | Gillard, Richard Edward, et al Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus London EC1N 2HA / GB | ||
| Former [2011/51] | Russell, Lindsey Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus London EC1N 2HA / GB | ||
| Former [2009/45] | Bailey, Lindsey Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus London EC1N 2HA / GB | ||
| Former [2009/30] | Bailey, Lindsey Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB | Application number, filing date | 07729379.3 | 22.05.2007 | [2009/30] | WO2007EP54940 | Priority number, date | EP20060114615 | 29.05.2006 Original published format: EP 06114615 | EP20060120117 | 05.09.2006 Original published format: EP 06120117 | [2009/30] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2007137968 | Date: | 06.12.2007 | Language: | EN | [2007/49] | Type: | A1 Application with search report | No.: | EP2079732 | Date: | 22.07.2009 | Language: | EN | The application published by WIPO in one of the EPO official languages on 06.12.2007 takes the place of the publication of the European patent application. | [2009/30] | Type: | B1 Patent specification | No.: | EP2079732 | Date: | 21.12.2011 | Language: | EN | [2011/51] | Type: | B9 Corrected patent specification | No.: | EP2079732 | Date: | 21.03.2012 | [2012/12] | Search report(s) | International search report - published on: | EP | 06.12.2007 | Classification | IPC: | C07D405/04, A61K31/501 | [2009/30] | CPC: |
C07D405/04 (EP,KR,US);
A61K31/501 (KR);
A61P1/00 (EP);
A61P1/04 (EP);
A61P11/00 (EP);
A61P11/02 (EP);
A61P19/02 (EP);
A61P25/06 (EP);
A61P25/20 (EP);
A61P25/28 (EP);
A61P3/04 (EP);
A61P3/06 (EP);
A61P3/10 (EP);
A61P35/00 (EP);
A61P37/08 (EP);
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR [2009/30] | Extension states | AL | 22.12.2008 | BA | 22.12.2008 | HR | 22.12.2008 | MK | 22.12.2008 | RS | 22.12.2008 | Title | German: | 3-(1,3-BENYODIOXOL-5-YL)-6- (4-CYCLOPROPYLPIPERAZIN-1-YL)-PYRIDAZIN, DESSEN SALZE UND SOLVATE UND DESSEN VERWENDUNG ALS HISTAMIN-H3-REZEPTORANTAGONIST | [2009/30] | English: | 3- (1, 3-BENZ0DI0X0L-5-YL) -6- (4-CYCLOPROPYLPIPERAZIN-1-YL) -PYRIDAZINE, ITS SALTS AND SOLVATES AND ITS USE AS HISTAMINE H3 RECEPTOR ANTAGONIST | [2009/30] | French: | 3-(1,3-BENZODIOXOL-5-YL)-6-(4-CYCLOPROPYLPIPERAZIN-1-YL)-PYRADINE, SES SELS ET SOLVATES ET SON UTILISATION COMME ANTAGONISTE DU RECEPTEUR D'HISTAMIN H3 | [2009/30] | Entry into regional phase | 22.12.2008 | National basic fee paid | 22.12.2008 | Designation fee(s) paid | 22.12.2008 | Examination fee paid | Examination procedure | 22.12.2008 | Examination requested [2009/30] | 15.02.2011 | Despatch of a communication from the examining division (Time limit: M04) | 26.04.2011 | Reply to a communication from the examining division | 08.07.2011 | Communication of intention to grant the patent | 05.10.2011 | Fee for grant paid | 05.10.2011 | Fee for publishing/printing paid | Divisional application(s) | EP11182795.2 / EP2402324 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 15.02.2011 | Opposition(s) | 24.09.2012 | No opposition filed within time limit [2012/48] | Fees paid | Renewal fee | 12.05.2009 | Renewal fee patent year 03 | 31.03.2010 | Renewal fee patent year 04 | 11.05.2011 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [DX]WO03066604 (NOVO NORDISK AS [DK], et al) [DX] 1-9 * the whole document; in particular, page 108, example 127 *; | [A]WO2004054973 (NOVO NORDISK AS [DK]) [A] 1-9* the whole document; in particular, claim 1, the definition of R14 * | by applicant | EP0214826 | EP0368187 | US5504188 | EP0705275 | WO9717345 | WO9726265 | EP0792290 | WO9741097 | WO9741119 | WO9741120 | WO9808871 | WO9845292 | WO9901423 | WO9903861 | WO9919313 | WO9942458 | EP0978512 | WO0023425 | WO0023415 | WO0023451 | WO0023445 | WO0023417 | WO0023416 | WO0037474 | WO0039088 | WO0041121 | WO0042026 | WO0050414 | WO0063191 | WO0063192 | WO0063193 | WO0063153 | WO0063196 | WO0063209 | WO0063190 | WO0063189 | WO0144191 | WO0166534 | WO0174810 | WO0174815 | WO0174773 | WO0174813 | WO0174814 | US6316475 | WO0212190 | WO03066604 | - DRUGS FUT, (1996), vol. 21, pages 507 - 20 | - PROGRESS IN DRUG RESEARCH, (1995), vol. 45, pages 107 - 65 | - MOLECULAR PHARMACOLOGY, (1999), vol. 55, pages 1101 - 7 | - NATURE, (2000), vol. 408, pages 860 - 4 | - EXPERT OPINION ON THERAPEUTIC PATENTS, (2000), vol. 10, pages 1045 - 55 | - ARCH PHARM PHARM MED CHEM, (1999), vol. 332, pages 389 - 98 | - J MED CHEM, (2000), vol. 43, pages 2362 - 70 | - ARCH PHARM PHARM MED CHEM, (1998), vol. 331, pages 395 - 404 | - 11 FARMACO, (1999), vol. 54, pages 684 - 94 | - DRUG DISCOVERY TODAY, (2005), vol. 10, pages 1613 - 17 | - NAT REV DRUG DISCOV, (2005), vol. 4, page 107 | - DRUG DEV RES, (2006), vol. 67, pages 651 - 665 | - THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (1998), vol. 287, pages 43 - 50 | - EXPERT OPINION ON INVESTIGATIONAL DRUGS, (2000), vol. 9, pages 2537 - 42 | - J PHARM SCI, (1977), vol. 66, page 2 |